TPCW
NTLA icon

TD Private Client Wealth’s Intellia Therapeutics NTLA Stock Holding History

TD Private Client Wealth’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08K Hold
84
– – ﹤0.01% 1374
2025
Q4 		$755 Sell
84
-42
-33% -$578 ﹤0.01% 1422
2025
Q3 		$2.18K Buy
126
+42
+50% +$517 ﹤0.01% 1239
2025
Q2 		$788 Buy
+84
New +$690 ﹤0.01% 1315
2021
Q4 		– Sell
-9
Closed -$1.21K – 1237
2021
Q3 		$1.21K Hold
9
– – ﹤0.01% 1078
2021
Q2 		$1.46K Buy
+9
New +$701 ﹤0.01% 1065

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TD Private Client Wealth's NTLA Position: Q1 2026 in Review

TD Private Client Wealth held its Intellia Therapeutics (NTLA) position steady in Q1 2026 at 84 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

TD Private Client Wealth first reported a position in NTLA in Q2 2021 and has held it in 6 quarters since. The position peaked at $2.18K in Q3 2025. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • TD Private Client Wealth held 84 shares of Intellia Therapeutics worth $1.08K as of Q1 2026.
  • TD Private Client Wealth left its Intellia Therapeutics share count unchanged in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q1 2026, its #1374 holding.
  • TD Private Client Wealth first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 6 quarters since.
  • TD Private Client Wealth's Intellia Therapeutics position peaked at $2.18K in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.